UnitedHealth offers over $3 billion for home health firm Amedisys
Reuters
Published Jun 05, 2023 10:34AM ET
Updated Jun 05, 2023 12:17PM ET
By Leroy Leo
(Reuters) - UnitedHealth Group (NYSE:UNH) on Monday made a surprise $3.26 billion all-cash offer to acquire Amedisys (NASDAQ:AMED) Inc, pitting itself against another healthcare company set to buy the home health and hospice care firm.
Interest in the home health sector has jumped since the pandemic as patients and caregivers increasingly prefer accessing medical services from the safety of their homes.
UnitedHealth, through its Optum unit, offered to pay $100 per share in cash, just a month after Amedisys agreed to be bought by Option Care Health (NASDAQ:OPCH) Inc for $97.38 per share in an all-stock deal.
If Optum's offer is accepted by Amedisys, the deal will expand UnitedHealth's presence in home healthcare that it bolstered this year through a $5.4 billion deal to buy Amedisys' rival, LHC Group (NASDAQ:LHCG).
Several analysts raised concerns that a UnitedHealth deal would likely face scrutiny from the Federal Trade Commission, given UnitedHealth's home health presence.
"First thing that comes to mind...FTC!" Jefferies analyst Brian Tanquilut said in a note, but added the transaction looks approvable after an objective analysis of (the) home healthcare market, which is fragmented and does not have a dominant player.
Amedisys' board has not yet determined whether Optum's offer is superior to Option Health's and is currently in exploratory discussions with the UnitedHealth unit.
Optum's offer was at a 26% premium to Amedisys' last close price, and sent the company's shares up 14% to $90.94 in morning trading.
Option Care said its offer was still a "compelling all-stock transaction". Its shares, which have fallen 11% since it announced the deal, rose 7% on Monday.
"Overall, this new wrinkle would seem to give Amedisys options should it have regrets about its original deal," Oppenheimer analyst Michael Wiederhorn said.
Amedisys will have to pay Option $106 million if it terminates their agreement.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.